Coherus Oncology, Inc. (CHRS) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Coherus Oncology, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -1.00x | 5.55x | -1.32x | -2.11x | -4.19x | 9.39x |
| P/B Ratio | 2.80x | -1.20x | -1.62x | -4.47x | 12.32x | 4.42x |
| P/S Ratio | 4.05x | 0.59x | 1.22x | 2.91x | 3.69x | 2.61x |
| Profitability | ||||||
| Gross Margin | 57.9% | 56.0% | 38.2% | 66.8% | 82.4% | 92.1% |
| Operating Margin | -425.7% | -41.8% | -79.0% | -121.7% | -80.8% | 32.9% |
| Net Margin | -403.8% | 10.7% | -92.5% | -138.2% | -87.9% | 27.8% |
| EBITDA Margin | -416.4% | 22.8% | -75.4% | -121.1% | -79.8% | 34.0% |
| Liquidity | ||||||
| Current Ratio | 1.46x | 1.21x | 1.43x | 2.75x | 3.64x | 5.27x |
| Quick Ratio | 1.43x | 0.96x | 1.24x | 2.47x | 3.42x | 4.97x |
| Leverage | ||||||
| Debt/Equity | 0.66x | -2.04x | -2.49x | -3.50x | 4.29x | 1.48x |
YoY = year-over-year change. Source: FMP..